BLLNNasdaqServices-Medical LaboratoriesFiscal year ends December 31
BillionToOne, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$101.03+2.91 (+2.97%)
Close on Oct 19, 2026
- Market cap
- $5.50B
- P/E (TTM)
- 721.6
- Dividend yield
- –
BillionToOne, Inc. revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q4 24 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|
| Prenatal | $350.95M | $317.55M | $277.11M | $234.22M | $196.75M | $145.90M | 88.3% | +78.4% |
| Oncology | $42.21M | $33.50M | $24.95M | $16.91M | $9.36M | $2.94M | 10.6% | +351.2% |
| Clinical trial support and other services | $4.25M | $3.49M | $3.05M | $3.01M | $2.93M | $3.74M | 1.1% | +45.2% |
By region
From the segment and revenue-disaggregation notes of BillionToOne's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.